Middle East Journal of Cancer

Current Issue

By Issue

By Author

By Subject

Author Index

Keyword Index

About Journal

Aims and Scope

Editorial Board

Publication Ethics

Indexing and Abstracting

Related Links

FAQ

Peer Review Process

News

Forms

Journal Metrics

Endometriosis-associated Ovarian Cancer, from Risk Factors to Survival Rate: A Systematic Review and Meta-Analysis

Document Type : Review Article(s)

Authors

1 Department of Obstetrics and Gynecology, School of Medicine, Maternal-Fetal Medicine Research Center, Shiraz University of Medical Sciences, Shiraz, Iran

2 Department of Obstetrics and Gynecology, School of Medicine, Laparoscopy Research Center, Shiraz University of Medical Sciences, Shiraz, Iran

3 Department of Obstetrics and Gynecology, School of Medicine, Infertility Research Center, Shiraz University of Medical Sciences, Shiraz, Iran

4 Department of Statistics, Shiraz University of Medical Sciences, Shiraz, Iran

10.30476/mejc.2024.101040.2012

Abstract

Background: Endometriosis experts recommend monitoring patients until menopause before considering surgery, with concerns about lesion malignancy. This meta-analysis aims to assess the prevalence and prognosis of endometriosis-associated ovarian cancer (EAOC) in various types of epithelial ovarian cancer (EOC), and compare risk factors with the non-EAOC group to improve disease management.
Method: In this review, PubMed, Science Direct, Scopus, Google Scholar, and Cochrane databases were searched for "endometriosis" and "ovarian cancer risk factor" from 2010 to 2023. Papers not reporting cancer prevalence or without a specified sample size were excluded. The study used statistical Cochran's Q and I2 index tests to evaluate heterogeneity and estimate ovarian cancer prevalence. Odds ratio was used to explore risk factors for cancer development.
Results: In our meta-analysis of 20 studies, 31,667 women with Non-EAOC were compared with 2826 women with EAOC across various factors: EOC subtypes, age, parity, menopausal status, FIGO stage, 5-year survival rate, and Ca125 levels. In our study, EAOC exhibited a 7.34% cancer incidence. While clear cell and endometrioid types were more common in EAOC than in the non-EAOC group, the low-grade serous type was the most prevalent malignancy.
Patients with early-stage EAOC have a 1.7 times higher 5-year survival rate compared with non-EAOC groups. EAOC is more common in nulliparous (2.243 times) and pre-menopausal women (2.169 times), but the CA125 levels are not significantly different between the groups.
Conclusion: Based on data and positive outlook, careful monitoring, considering medical history, and avoiding early surgery are highly recommended in endometriotic patients.

Highlights

Elham Askary (Google Scholar)

Keywords

Main Subjects

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination, and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.30476/mejc.2024.101040.2012

References
  1. Nezhat F, Datta MS, Hanson V, Pejovic T, Nezhat C, Nezhat C. The relationship of endometriosis and ovarian malignancy: a review. Fertil Steril. 2008;90(5):1559-70. doi: 10.1016/j.fertnstert.2008.08.007.
  2. Kumar S, Munkarah A, Arabi H, Bandyopadhyay S, Semaan A, Hayek K, et al. Prognostic analysis of ovarian cancer associated with endometriosis. Am J Obstet Gynecol. 2011;204(1):63.e1-7. doi:10.1016/j.ajog.2010.08.017.
  3. Webb PM, Jordan SJ. Epidemiology of epithelial ovarian cancer. Best Pract Res Clin Obstet Gynaecol. 2017;41:3-14. doi: 10.1016/j.bpobgyn.2016.08.006.
  4. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7-30. doi: 10.3322/caac.21442.
  5. Van Gorp T, Amant F, Neven P, Vergote I, Moerman P. Endometriosis and the development of malignant tumours of the pelvis. A review of literature. Best Pract Res Clin Obstet Gynaecol. 2004;18(2):349-71. doi: 10.1016/j.bpobgyn.2003.03.001.
  6. Hermens M, van Altena AM, van der Aa M, Bulten J, van Vliet HAAM, Siebers AG, et al. Ovarian cancer prognosis in women with endometriosis: a retrospective nationwide cohort study of 32,419 women. Am J Obstet Gynecol. 2021;224(3):284.e1-284.e10. doi: 10.1016/j.ajog.2020.08.056.
  7. Pearce CL, Templeman C, Rossing MA, Lee A, Near AM, Webb PM, et al. Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case-control studies. Lancet Oncol. 2012;13(4):385-94. doi: 10.1016/S1470-2045(11)70404-1.
  8. Buis CC, van Leeuwen FE, Mooij TM, Burger CW; OMEGA Project Group. Increased risk for ovarian cancer and borderline ovarian tumours in subfertile women with endometriosis. Hum Reprod. 2013;28(12):3358-69. doi: 10.1093/humrep/det340.
  9. Poole EM, Lin WT, Kvaskoff M, De Vivo I, Terry KL, Missmer SA. Endometriosis and risk of ovarian and endometrial cancers in a large prospective cohort of U.S. nurses. Cancer Causes Control. 2017;28(5):437-45. doi: 10.1007/s10552-017-0856-4.
  10. Prat J. Pathology of borderline and invasive cancers. Best Pract Res Clin Obstet Gynaecol. 2017;41:15-30. doi: 10.1016/j.bpobgyn.2016.08.007.
  11. Sampson JA. Endometrial carcinoma of the ovary arising in endometrial tissue in that organ. Arch Surg. 1925;10(1):1-72. doi:10.1001/archsurg.1925.01120100007001.
  12. SCOTT RB. Malignant changes in endometriosis. Obstet Gynecol. 1953;2(3):283-9.
  13. Shih IeM, Kurman RJ. Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Am J Pathol. 2004;164(5):1511-8. doi: 10.1016/s0002-9440(10)63708-x.
  14. Ogawa S, Kaku T, Amada S, Kobayashi H, Hirakawa T, Ariyoshi K, et al. Ovarian endometriosis associated with ovarian carcinoma: a clinicopathological and immunohistochemical study. Gynecol Oncol. 2000;77(2):298-304. doi: 10.1006/gyno.2000.5765.
  15. Kokcu A. Relationship between endometriosis and cancer from current perspective. Arch Gynecol Obstet. 2011;284(6):1473-9. doi: 10.1007/s00404-011-2047-y.
  16. Kondi-Pafiti A, Papakonstantinou E, Iavazzo C, Grigoriadis C, Salakos N, Gregoriou O. Clinicopathological characteristics of ovarian carcinomas associated with endometriosis. Arch Gynecol Obstet. 2012;285(2):479-83. doi: 10.1007/s00404-011-1957-z.
  17. Sayasneh A, Tsivos D, Crawford R. Endometriosis and ovarian cancer: a systematic review. ISRN Obstet Gynecol. 2011;2011:140310. doi: 10.5402/2011/140310.
  18. Somigliana E, Vigano' P, Parazzini F, Stoppelli S, Giambattista E, Vercellini P. Association between endometriosis and cancer: a comprehensive review and a critical analysis of clinical and epidemiological evidence. Gynecol Oncol. 2006;101(2):331-41. doi: 10.1016/j.ygyno.2005.11.033.
  19. Kim SY, Lee JR. Fertility preservation option in young women with ovarian cancer. Future Oncol. 2016;12(14):1695-8. doi: 10.2217/fon-2016-0181.
  20. Viganò P, Parazzini F, Somigliana E, Vercellini P. Endometriosis: epidemiology and aetiological factors. Best Pract Res Clin Obstet Gynaecol. 2004;18(2):177-200. doi: 10.1016/j.bpobgyn.2004.01.007.
  21. Chapron C, Marcellin L, Borghese B, Santulli P. Rethinking mechanisms, diagnosis and management of endometriosis. Nat Rev Endocrinol. 2019;15(11):666-82. doi: 10.1038/s41574-019-0245-z.
  22. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177-88. doi: 10.1016/0197-2456(86)90046-2.
  23. Quality Assessment of systematic review and meta-analysis. [Internet] The National Heart, Lung, and Blood Institute 2013 (NIH). [updated at: July 2021] Available at: https://www.nhlbi.nih.gov/health-topics/study-quality-assessment-tools
  24. Ju UC, Kang WD, Kim SM. The effect of concurrent endometriosis on the prognosis of women with ovarian clear cell or endometrioid carcinoma. Int J Gynaecol Obstet. 2019;146(2):177-83. doi: 10.1002/ijgo.12861.
  25. Acién P, Velasco I, Acién M, Capello C, Vela P. Epithelial ovarian cancers and endometriosis. Gynecol Obstet Invest. 2015;79(2):126-35. doi: 10.1159/000367597.
  26. Bas-Esteve E, Pérez-Arguedas M, Guarda-Muratori GA, Acién M, Acién P. Endometriosis and ovarian cancer: Their association and relationship. Eur J Obstet Gynecol Reprod Biol X. 2019;3:100053. doi: 10.1016/j.eurox.2019.100053.
  27. Boyraz G, Selcuk I, Yazıcıoğlu A, Tuncer ZS. Ovarian carcinoma associated with endometriosis. Eur J Obstet Gynecol Reprod Biol. 2013;170(1):211-3. doi: 10.1016/j.ejogrb.2013.06.001.
  28. Lim MC, Chun KC, Shin SJ, Lee IH, Lim KT, Cho CH, et al. Clinical presentation of endometrioid epithelial ovarian cancer with concurrent endometriosis: a multicenter retrospective study. Cancer Epidemiol Biomarkers Prev. 2010;19(2):398-404. doi: 10.1158/1055-9965.EPI-09-0750.
  29. Mangili G, Bergamini A, Taccagni G, Gentile C, Panina P, Viganò P, et al. Unraveling the two entities of endometrioid ovarian cancer: a single center clinical experience. Gynecol Oncol. 2012;126 (3):403-7. doi: 10.1016/j.ygyno.2012.05.007.
  30. Li Q, Sun Y, Zhang X, Wang L, Wu W, Wu M, et al. Endometriosis-associated ovarian cancer is a single entity with distinct clinicopathological characteristics. Cancer Biol Ther. 2019;20(7):1029-34. doi: 10.1080/15384047.2019.1595278.
  31. Cai Y, Yin J, Jin Y, Li Y, Wu M, Yang J, et al. Endometriosis-associated ovarian cancer is not a distinct clinical entity among young patients: A 12-year cohort study. Eur J Surg Oncol. 2020;46(5):876-82. doi: 10.1016/j.ejso.2019.11.517.
  32. Ye S, Yang J, You Y, Cao D, Bai H, Lang J, et al. Comparative study of ovarian clear cell carcinoma with and without endometriosis in People's Republic of China. Fertil Steril. 2014;102(6):1656-62. doi: 10.1016/j.fertnstert.2014.08.008.
  33. Bounous VE, Ferrero A, Fuso L, Ravarino N, Ceccaroni M, Menato G, et al. Endometriosis-associated ovarian cancer: A distinct clinical entity? Anticancer Res. 2016;36(7):3445-9.
  34. Son JH, Yoon S, Kim S, Kong TW, Paek J, Chang SJ, et al. Clinicopathologic characteristics of ovarian clear cell carcinoma in the background of endometrioma: a surveillance strategy for an early detection of malignant transformation in patients with asymptomatic endometrioma. Obstet Gynecol Sci. 2019;62(1):27-34. doi: 10.5468/ogs.2019.62.1.27.
  35. Bai H, Cao D, Yuan F, Sha G, Yang J, Chen J, et al. Prognostic value of endometriosis in patients with stage I ovarian clear cell carcinoma: Experiences at three academic institutions. Gynecol Oncol. 2016;143(3):526-31. doi: 10.1016/j.ygyno.2016.10.009.
  36. Qiu L, Wang S, Lang JH, Shen K, Huang HF, Pan LY, et al. The occurrence of endometriosis with ovarian carcinomas is not purely coincidental. Eur J Obstet Gynecol Reprod Biol. 2013;170(1):225-8. doi: 10.1016/j.ejogrb.2013.06.015.
  37. Muangtan S, Suknikhom W, Sananpanichkul P, Bhamarapravatana K, Suwannarurk K. Epithelial ovarian cancer with endometriosis is not associated with menopausal status: a co-association study at Prapokklao Hospital. Asian Pac J Cancer Prev. 2018;19(5):1337-41. doi: 10.22034/APJCP.2018.19.5.1337.
  38. Wang S, Qiu L, Lang JH, Shen K, Yang JX, Huang HF, et al. Clinical analysis of ovarian epithelial carcinoma with coexisting pelvic endometriosis. Am J Obstet Gynecol. 2013;208(5):413.e1-5. doi: 10.1016/j.ajog.2012.12.004.
  39. Paik ES, Lee YY, Shim M, Choi HJ, Kim TJ, Choi CH, et al. Timing and patterns of recurrence in epithelial ovarian cancer patients with no gross residual disease after primary debulking surgery. Aust N Z J Obstet Gynaecol. 2016;56(6):639-47. doi: 10.1111/ajo.12529.
  40. Ren T, Wang S, Sun J, Qu JM, Xiang Y, Shen K, et al. Endometriosis is the independent prognostic factor for survival in Chinese patients with epithelial ovarian carcinoma. J Ovarian Res. 2017;10(1):67. doi: 10.1186/s13048-017-0363-y.
  41. Lu J, Tao X, Zhou J, Lu Y, Wang Z, Liu H, et al. Improved clinical outcomes of patients with ovarian carcinoma arising in endometriosis. 2017;8(4):5843-52. doi: 10.18632/oncotarget.13967.
  42. Heidemann LN, Hartwell D, Heidemann CH, Jochumsen KM. The relation between endometriosis and ovarian cancer - a review. Acta Obstet Gynecol Scand. 2014;93(1):20-31. doi: 10.1111/aogs.12255.
  43. Fukunaga M, Nomura K, Ishikawa E, Ushigome S. Ovarian atypical endometriosis: its close association with malignant epithelial tumours. 1997;30(3):249-55. doi: 10.1046/j.1365-2559.1997.d01-592.x.
  44. Ogawa S, Kaku T, Amada S, Kobayashi H, Hirakawa T, Ariyoshi K, et al. Ovarian endometriosis associated with ovarian carcinoma: a clinicopathological and immunohistochemical study. Gynecol Oncol. 2000;77(2):298-304. doi: 10.1006/gyno.2000.5765.
  45. Jimbo H, Yoshikawa H, Onda T, Yasugi T, Sakamoto A, Taketani Y. Prevalence of ovarian endometriosis in epithelial ovarian cancer. Int J Gynaecol Obstet. 1997;59(3):245-50. doi: 10.1016/s0020-7292(97)00238-5.
  46. Vercellini P, Parazzini F, Bolis G, Carinelli S, Dindelli M, Vendola N, et al. Endometriosis and ovarian cancer. Am J Obstet Gynecol. 1993;169(1):181-2. doi: 10.1016/0002-9378(93)90159-g.
  47. Shafrir AL, Babic A, Tamimi RM, Rosner BA, Tworoger SS, Terry KL. Reproductive and hormonal factors in relation to survival and platinum resistance among ovarian cancer cases. Br J Cancer. 2016;115(11):1391-9. doi: 10.1038/bjc.2016.316.
  48. Kurman RJ, Shih IeM. The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am J Surg Pathol. 2010;34(3):433-43. doi: 10.1097/PAS.0b013e3181cf3d79.
  49. Van Gorp T, Amant F, Neven P, Vergote I, Moerman P. Endometriosis and the development of malignant tumours of the pelvis. A review of literature. Best Pract Res Clin Obstet Gynaecol. 2004;18(2):349-71. doi: 10.1016/j.bpobgyn.2003.03.001.
  50. Barreta A, Sarian L, Ferracini AC, Eloy L, Brito ABC, de Angelo Andrade L, et al. Endometriosis-associated ovarian cancer: Population characteristics and prognosis. Int J Gynecol Cancer. 2018;28(7):1251-7. doi: 10.1097/IGC.0000000000001317.
  51. Garrett LA, Growdon WB, Goodman A, Boruta DM, Schorge JO, del Carmen MG. Endometriosis-associated ovarian malignancy: a retrospective analysis of presentation, treatment, and outcome. J Reprod Med. 2013;58(11-12):469-76.
  52. Wang S, Qiu L, Lang JH, Shen K, Huang HF, Pan LY, et al. Prognostic analysis of endometrioid epithelial ovarian cancer with or without endometriosis: a 12-year cohort study of Chinese patients. Am J Obstet Gynecol. 2013;209(3):241.e1-9. doi: 10.1016/j.ajog.2013.05.032.
  53. Scarfone G, Bergamini A, Noli S, Villa A, Cipriani S, Taccagni G, et al. Characteristics of clear cell ovarian cancer arising from endometriosis: a two center cohort study. Gynecol Oncol. 2014;133(3):480-4. doi: 10.1016/j.ygyno.2014.03.017.
  54. Riccio LDGC, Santulli P, Marcellin L, Abrão MS, Batteux F, Chapron C. Immunology of endometriosis. Best Pract Res Clin Obstet Gynaecol. 2018;50:39-49. doi: 10.1016/j.bpobgyn.2018.01.010.
  55. Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, Regnani G, et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med. 2003;348(3):203-13. doi: 10.1056/NEJMoa020177.
  56. Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med. 2004;10(9):942-9. doi: 10.1038/nm1093.
  57. Wong AS, Leung PC. Role of endocrine and growth factors on the ovarian surface epithelium. J Obstet Gynaecol Res. 2007;33(1):3-16. doi: 10.1111/j.1447-0756.2007.00478.x.
  58. Jatoi A, Foster NR, Kalli KR, Vierkant RA, Zhang Z, Larson MC, et al. Prior oral contraceptive use in ovarian cancer patients: assessing associations with overall and progression-free survival. BMC Cancer. 2015;15:711. doi: 10.1186/s12885-015-1774-z.
  59. Munksgaard PS, Blaakaer J. The association between endometriosis and gynecological cancers and breast cancer: a review of epidemiological data. Gynecol Oncol. 2011;123(1):157-63. doi: 10.1016/j.ygyno.2011.06.017.
  60. Vercellini P, Viganò P, Buggio L, Makieva S, Scarfone G, Cribiù FM, et al. Perimenopausal management of ovarian endometriosis and associated cancer risk: When is medical or surgical treatment indicated? Best Pract Res Clin Obstet Gynaecol. 2018;51:151-68. doi: 10.1016/j.bpobgyn.2018.01.017.
  61. Noli S, Cipriani S, Scarfone G, Villa A, Grossi E, Monti E, et al. Long term survival of ovarian endometriosis associated clear cell and endometrioid ovarian cancers. Int J Gynecol Cancer. 2013;23(2):244-8. doi: 10.1097/IGC.0b013e31827aa0bb.
  62. Tariverdian N, Theoharides TC, Siedentopf F, Gutiérrez G, Jeschke U, Rabinovich GA, et al. Neuroendocrine-immune disequilibrium and endometriosis: an interdisciplinary approach. Semin Immunopathol. 2007;29(2):193-210. doi: 10.1007/s00281-007-0077-0.
  63. Suzuki F, Akahira J, Miura I, Suzuki T, Ito K, Hayashi S, et al. Loss of estrogen receptor beta isoform expression and its correlation with aberrant DNA methylation of the 5'-untranslated region in human epithelial ovarian carcinoma. Cancer Sci. 2008;99(12):2365-72. doi: 10.1111/j.1349-7006.2008.00988.x.
  64. Soslow RA. Histologic subtypes of ovarian carcinoma: an overview. Int J Gynecol Pathol. 2008;27(2):161-74. doi: 10.1097/PGP.0b013e31815ea812.
  65. Mandai M, Yamaguchi K, Matsumura N, Baba T, Konishi I. Ovarian cancer in endometriosis: molecular biology, pathology, and clinical management. Int J Clin Oncol. 2009;14(5):383-91. doi: 10.1007/s10147-009-0935-y.
  66. Tanase Y, Yamada Y, Shigetomi H, Kajihara H, Oonogi A, Yoshizawa Y, et al. Modulation of estrogenic action in clear cell carcinoma of the ovary (Review). Exp Ther Med. 2012;3(1):18-24. doi: 10.3892/etm.2011.376.
  67. Worley MJ, Welch WR, Berkowitz RS, Ng SW. Endometriosis-associated ovarian cancer: a review of pathogenesis. Int J Mol Sci. 2013;14(3):5367-79. doi: 10.3390/ijms14035367.
  68. Vara J, Pagliuca M, Springer S, Gonzalez de Canales J, Brotons I, Yakcich J, et al. O-RADS classification for ultrasound assessment of adnexal masses: Agreement between IOTA lexicon and ADNEX model for assigning risk group. Diagnostics (Basel). 2023;13(4):673. doi: 10.3390/diagnostics13040673.
  69. Orezzoli JP, Russell AH, Oliva E, Del Carmen MG, Eichhorn J, Fuller AF. Prognostic implication of endometriosis in clear cell carcinoma of the ovary. Gynecol Oncol. 2008;110(3):336-44. doi: 10.1016/j.ygyno.2008.05.025.
  70. Andersen MR, Goff BA, Lowe KA, Scholler N, Bergan L, Drescher CW, et al. Use of a Symptom Index, CA125, and HE4 to predict ovarian cancer. Gynecol Oncol. 2010;116(3):378-83. doi: 10.1016/j.ygyno.2009.10.087.
  71. Li Q, Sun Y, Zhang X, Wang L, Wu W, Wu M, et al. Endometriosis-associated ovarian cancer is a single entity with distinct clinicopathological characteristics. Cancer Biol Ther. 2019;20(7):1029-34. doi: 10.1080/15384047.2019.1595278.
Middle East Journal of Cancer

Articles in Press, Accepted Manuscript
Available Online from 18 May 2024
Files
Share
How to cite
Statistics